BioMarin Pharmaceutical just turned a courtroom fight into a revenue stream, and its stock jumped 5% the moment the deal became public.

The settlement, announced August 31, ends a global patent dispute between BioMarin and Danish drugmaker Ascendis Pharma over Yuviwel, Ascendis's newly launched treatment for achondroplasia. Achondroplasia is a genetic condition that restricts bone growth and is one of the most common forms of dwarfism. BioMarin had spent decades researching the underlying biology of that condition and holds patents it argued Ascendis's drug violated. Ascendis disagreed. The two companies had been fighting in multiple countries simultaneously, including before the US International Trade Commission and in federal court in California.

The fight is over now, but Ascendis will be writing BioMarin checks for years.

The terms

Under the agreement, Ascendis will pay BioMarin a royalty equal to 20% of Yuviwel's net sales in the United States and 18% of net sales in the European Union, Brazil, and South Korea. Those payments apply retroactively to Yuviwel's first commercial sale and continue through May 20, 2030. In return, BioMarin grants Ascendis a license to continue selling and developing the drug without further legal interference.

For BioMarin, this is a clean win on paper. It did not have to prove patent infringement in court or navigate years of additional litigation across multiple jurisdictions. It gets a guaranteed income tied directly to however well Yuviwel sells, and its own competing treatment, Voxzogo, remains on the market. BioMarin CEO Alexander Hardy framed the outcome as a vindication of long-term investment in rare-disease research.

Ascendis's CEO Jan Mikkelsen put a confident face on paying its competitor a fifth of every US dollar Yuviwel earns, arguing that the royalty rate itself reflects the drug's commercial strength and the significant need it fills.

What this means beyond the balance sheet

Royalty arrangements like this one are increasingly how patent disputes in pharmaceuticals resolve. Litigation is slow, expensive, and unpredictable. A negotiated royalty lets both companies keep selling, keeps drugs available to patients, and converts legal uncertainty into a predictable line item. For BioMarin, the structure essentially lets it profit from a competitor's commercial success, at least until 2030.

The bigger issue here is what this signals about competition in rare-disease markets. Achondroplasia affects a relatively small number of patients, but the drugs that treat it carry premium prices, which is why two companies were willing to fight across multiple continents over market access. When patient populations are small, every sale matters enormously, and patent control can determine whether a competitor gets in at all.

For patients and families affected by achondroplasia, the settlement is probably neutral in the short run. Both drugs remain available. The royalty burden Ascendis now carries could, in theory, affect how aggressively it prices or promotes Yuviwel over the next four years, but the source material does not specify any pricing changes, so that remains speculative.

What is clear is that BioMarin's patents held enough weight to extract a meaningful settlement from a well-funded rival, and that the structure of this deal, where the loser pays the winner a percentage of sales rather than a lump sum, aligns both companies' incentives with Yuviwel actually reaching patients. The more Ascendis sells, the more BioMarin earns. That is an unusual dynamic between competitors, and it will be worth watching whether it shapes how aggressively BioMarin continues investing in its own competing product through 2030.